Stocks › BBIO
BridgeBio Pharma, Inc.
BBIO·Nasdaq·
United States·USD
United States·USD$66.96
+0.82 (+1.24%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
BBIO
BridgeBio Pharma, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BBIOS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of BBIO by members of U.S. Congress · 7 on record · 6 in the last 12 months
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
Jun 8, 2026 | May 11, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
May 8, 2026 | Apr 29, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
Apr 7, 2026 | Mar 18, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
Apr 7, 2026 | Mar 19, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
Apr 7, 2026 | Mar 3, 2026 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
Oct 10, 2025 | Sep 22, 2025 | Filing ↗ |
| Gilbert Ray Cisneros, Jr.House · D · CA |
BBIOBridgeBio Pharma, Inc. · Stock |
Purchase $1,001 - $15,000 |
Sep 12, 2025 | Aug 8, 2025 | Filing ↗ |
Whale Activity
Position changes in BBIO reported for 2026-06-30 by 24 tracked institutional filers
- Increased8
- New2
- Held1
- Decreased5
- Closed0
- No prior filing8
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.3M | $766.2M | decreased |
| VIKING GLOBAL INVESTORS LP | 9.9M | $741.0M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.9M | $588.3M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.7M | $570.3M | decreased |
| TWO SIGMA INVESTMENTS, LP | 4.7M | $351.7M | increased |
| CITADEL ADVISORS LLC | 3.8M | $280.0M | increased |
| D. E. Shaw & Co., Inc. | 3.6M | $270.6M | increased |
| CAPSTONE INVESTMENT ADVISORS, LLC | 69.9M | $124.5M | — |
| Point72 Asset Management, L.P. | 1.5M | $113.6M | new |
| Laurion Capital Management LP | 1.4M | $100.7M | — |
| RENAISSANCE TECHNOLOGIES LLC | 856.8K | $63.8M | increased |
| BOUSSARD & GAVAUDAN GESTION SAS | 29.0K | $51.0M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by BBIO insiders, by quarter · Form 4
Recent Insider Transactions
760 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Kumar NeilChief Executive Officer · Director | Sale | −8,721 | $69.01 | $602K | Sep 17, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,279 | $69.57 | $89K | Sep 17, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −8,100 | $83.86 | $679K | Aug 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,800 | $84.69 | $152K | Aug 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −100 | $85.65 | $9K | Aug 19, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,900 | $81.15 | $154K | Aug 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −17.3K | $82.21 | $1.4M | Aug 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −14.6K | $82.99 | $1.2M | Aug 18, 2026 | Form 4 ↗ |
| Kumar NeilChief Executive Officer · Director | Sale | −1,199 | $83.77 | $100K | Aug 18, 2026 | Form 4 ↗ |
| Apuli MaricelChief Accounting Officer | Sale | −2,000 | $80.06 | $160K | Jul 30, 2026 | Form 4 ↗ |
| Ellis AndreaDirector · Director | Sale | −17.2K | $84.00 | $1.4M | Jul 9, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director · Director | Sale | −36.2K | $84.00 | $3.0M | Jul 9, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director · Director | Sale | −112.4K | $90.00 | $10.1M | Jul 9, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director | Sale | −37.2K | $70.00 | $2.6M | Jun 24, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director | Option exercise | +17.2K | $16.75 | $288K | Jun 24, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director | Option exercise | +20.0K | $8.45 | $169K | Jun 24, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director | Sale | −2,196 | $68.57 | $151K | Jun 23, 2026 | Form 4 ↗ |
| Valantine HannahDirector | Sale | −2,196 | $68.57 | $151K | Jun 23, 2026 | Form 4 ↗ |
| Cook Jennifer E.Director | Grant / award | +3,990 | $0.00 | $0 | Jun 22, 2026 | Form 4 ↗ |
| Valantine HannahDirector | Sale | −2,808 | $68.00 | $191K | Jun 22, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding BBIO · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.6M | $417.1M | 0.02% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 4.0M | $300.9M | 0.16% | Jun 30, 2026 |
| iShares Russell 2000 ETF iSHARES TRUST | 3.9M | $287.9M | 0.40% | Mar 31, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 3.2M | $253.3M | 0.66% | Jul 31, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 2.3M | $173.6M | 0.37% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.0M | $147.1M | 0.15% | Jun 30, 2026 |
| Janus Henderson Enterprise Fund Janus Investment Fund | 1.9M | $142.2M | 0.64% | Jun 30, 2026 |
| VANGUARD EXPLORER FUND | 1.7M | $138.2M | 0.62% | Jul 31, 2026 |
| Janus Henderson Global Life Sciences Fund Janus Investment Fund | 1.6M | $118.5M | 2.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $111.5M | 0.34% | Apr 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list BBIO's shares (CUSIP 10806X102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- George R. RobertsSCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - Henry R. KravisSCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - KKR Management LLPSCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - KKR & Co. Inc.SCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - KKR Group Co. Inc.SCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - KKR Group Holdings Corp.SCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - KKR Group Partnership L.P.SCHEDULE 13D/A · activist (13D) · 9.2M shares4.7%
Aug 17, 2026 · ↗ - KKR Genetic Disorder GP LLCSCHEDULE 13D/A · activist (13D) · 8.3M shares4.2%
Aug 17, 2026 · ↗ - KKR Genetic Disorder L.P.SCHEDULE 13D/A · activist (13D) · 8.3M shares4.2%
Aug 17, 2026 · ↗ - Farallon Capital F5 Master I, L.P.SCHEDULE 13G/A · passive (13G) · 0 shares0.0%
Aug 3, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming BridgeBio Pharma, Inc. as client
No lobbying filings found naming BridgeBio Pharma, Inc. as the client.
Government Contracts
Federal awards to BridgeBio Pharma, Inc. · USAspending
No federal contract awards found for BridgeBio Pharma, Inc..
U.S. Patents
Recent USPTO applications naming BridgeBio Pharma, Inc.
No USPTO patent applications found for BridgeBio Pharma, Inc..
Annual Financials
From BBIO's 10-K filings · XBRL
No annual XBRL figures on record for BBIO. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in BBIO's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01, 9.01Other eventsAug 31, 2026
EDGAR ↗ - 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsAug 17, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJul 22, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.02, 3.03, 5.03, 7.01, 9.01Material agreement · Unregistered sale of equity · Modification of rightsJul 2, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteJun 26, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 27, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 13, 2026
EDGAR ↗ - 8-K · Items 1.01, 1.02, 9.01Material agreement · Termination of agreementMay 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 8.01Results of operations · Other eventsMay 7, 2026
EDGAR ↗
About BridgeBio Pharma, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersPALO ALTO, CA
IncorporatedDE
SEC CIK0001743881 ↗
Former namesBridgeBio Pharma LLC